Wu, Yi-Long

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 8,261

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 4,081

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 3,381

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,379

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,190

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,978

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,581

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,574

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,216

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,151

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,111

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,059

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,002

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 959

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., et al. (2015) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 738

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 646

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 517

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Mok, T., Wu, Y.-L., Lee, J. S., Yu, C.-J., Sriuranpong, V., Sandoval-Tan, J., Ladrera, G., Thongprasert, S., Srimuninnimit, V., Liao, M., et al. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 468

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2015) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 464

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 440

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Lee, M., Linke, R., Rosell, R., Corral, J., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 439

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 413

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 361

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 357